Articles

Get Ready for BIO 2026: Key Insights and What to Expect

The BIO 2026 event in San Diego promises to be a pivotal gathering for the biotech industry. Attendees can expect insights on emerging trends and key company developments.

Replimune's Third FDA Approval Attempt and Pfizer's China Deal

This article analyzes Replimune's third attempt for FDA approval and Pfizer's recent deal in China, highlighting implications for investors and pharma teams.

FDA's Restructuring Opportunity Amid China Competition

This article discusses the FDA's chance to restructure following recent challenges and the implications for the pharmaceutical industry amid competition from China.

Friday Five: Key Regulatory Updates in Pharma

This article covers significant regulatory updates impacting the pharmaceutical industry, including GSK's breakthrough in hepatitis B and Eli Lilly's advancements in prevention.

Zydus Lifesciences Secures FDA Priority Review for Liver Disease Drug

Zydus Lifesciences has secured a priority review from the US FDA for its liver disease drug application. This development could significantly impact the company's market positioning.

BioNTech, Pfizer Bispecific Data at ASCO

BioNTech and Pfizer present promising bispecifics data, while FDA's Pazdur highlights potential opportunities. Discover the implications for the pharma sector.

Philips Partners with Disney to Alleviate MRI Anxiety in Children

Philips has partnered with Disney to create a more comforting MRI experience for children. This innovative approach aims to reduce anxiety and improve patient outcomes.

GLP-1 Microdoses: FDA Warnings Clinicians Need

GLP-1 microdosing has migrated from social media into clinics and compounding channels. FDA safety communications on compounded semaglutide and tirzepatide explain why quality and dose measurement—not influencer protocols—should set the clinical bar.

XPRIZE Healthspan: Longevity Race Explained

XPRIZE Healthspan—a $101 million, multi-year competition—has become a focal point for translational geroscience. Jamie Justice’s role as executive director puts scientific measurement of restored function, not wellness marketing, at the center of the race.

Bristol Myers Unveils Next-Gen Blood Cancer Drug Data

Bristol Myers has revealed promising data for its next-generation blood cancer drug, Mezigdomide. This article explores the implications for the pharmaceutical landscape.

Replimune's Third Attempt at Cancer Drug Approval: Insights from FDA Talks

Replimune is making its third attempt to gain FDA approval for its cancer drug following productive discussions. This article explores the implications for investors and pharma teams.

Modernizing Patient Support in Pharma Amid Rising Young Adult Cancer Rates

As young adult cancer rates increase, pharmaceutical companies are urged to modernize their patient support systems. This article outlines key developments and implications for the industry.

Trump Administration's Overhaul of Federal Grantmaking: Impacts on Pharma

The Trump administration's proposed overhaul of the federal grantmaking process raises concerns among researchers. This article explores the potential impacts on the pharmaceutical industry.

Massachusetts Sues UnitedHealth Over Medicaid Fraud Allegations

Massachusetts has filed a lawsuit against UnitedHealth, alleging fraudulent practices in Medicaid plans for seniors. This article explores the implications for the pharmaceutical industry.

Fierce Pharma Asia: Key Insights on Recent Deals and Trends

This article provides a comprehensive overview of the latest developments in the pharmaceutical industry, focusing on Pfizer's $10B Innovent deal and Astellas' strategic roadmap.

Which Vaccines Will Curb the Ebola Outbreak? WHO Debates

The WHO is currently debating which vaccines will effectively curb the ongoing Ebola outbreak. This article explores the implications for pharmaceutical teams and investors.

Can a Chaotic FDA Still Deliver on Faster Drug Development?

This article examines the FDA's chaotic environment and its impact on drug development timelines. We analyze the implications for pharmaceutical teams navigating these changes.

Pfizer and Innovent's $10B Cancer Drug Deal: Key Insights

Pfizer and Innovent have entered a significant $10B deal focusing on cancer therapeutics. This article delves into the implications for the pharmaceutical landscape.

Allogene CEO Departure and Agios Drug Setback: What It Means for Pharma

Allogene's CEO is stepping down amid significant challenges, while Agios faces a setback with its drug failing a key test. This article explores the implications for the industry.

Zydus Therapeutics' Saroglitazar Receives FDA Priority Review

Zydus Therapeutics' saroglitazar has received priority review from the US FDA, marking a significant regulatory milestone. This analysis explores the implications for investors and pharma teams.